Pazan, Farhad
,
Weiss, Christel
Wehling, Martin
Article History
First Online: 2 April 2019
Compliance with Ethical Standards
: Martin Wehling was employed by AstraZeneca R&D, Mölndal, as the director of discovery medicine (translational medicine) from 2003 to 2006, while on sabbatical leave from his professorship at the University of Heidelberg. Since returning to this position in January 2007, he has received lecturing and consulting fees from Sanofi-Aventis, Bayer, Berlin-Chemie, Boehringer-Ingelheim, Aspen, Novartis, Takeda, Roche, Pfizer, Bristol-Myers, Daichii-Sankyo, Lilly, Otsuka, Novo-Nordisk, Shire, and LEO Pharma. Farhad Pazan and Christel Weiss have no conflicts of interest that are directly relevant to the contents of this letter.